Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Silvia Paola Corona,1 Daniele Generali2 1Radiation Oncology Department, Peter MacCallum Cancer Centre, Bentleigh East, VIC, Australia; 2Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy Abstract: Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in t